News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
Reinforcing commitment to ethical and sustainable growth
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
Subscribe To Our Newsletter & Stay Updated
